Bimekizumab in Psoriatic Arthritis: 12-Month Retention, Multidomain Effectiveness, and Impact of Prior Interleukin-17 Inhibition in a Real-World Cohort
Bimekizumab in Psoriatic Arthritis: 12-Month Retention, Multidomain Effectiveness, and Impact of Prior Interleukin-17 Inhibition in a Real-World Cohort. // Joint Bone Spine. – URL: https://www.sciencedirect.com/science/article/pii/S1297319X26001272?dgcid=rss_sd_all
Bimekizumab in Psoriatic Arthritis: 12-Month Retention, Multidomain Effectiveness, and Impact of Prior Interleukin-17 Inhibition in a Real-World Cohort. Joint Bone Spine. https://www.sciencedirect.com/science/article/pii/S1297319X26001272?dgcid=rss_sd_all
“Bimekizumab in Psoriatic Arthritis: 12-Month Retention, Multidomain Effectiveness, and Impact of Prior Interleukin-17 Inhibition in a Real-World Cohort.” Joint Bone Spine.
@article{article51310,
title = {Bimekizumab in Psoriatic Arthritis: 12-Month Retention, Multidomain Effectiveness, and Impact of Prior Interleukin-17 Inhibition in a Real-World Cohort},
journal = {Joint Bone Spine},
url = {https://www.sciencedirect.com/science/article/pii/S1297319X26001272?dgcid=rss_sd_all}
}